Category: Finance
ASX Health Stocks: Neuren’s sales come in at top of guidance range, crushing short seller’s claims
Neuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug shows efficacy in animal testing Neuren’s Daybue sales meet [more…]
Market Highlights: Bitcoin up again, Microsoft makes another huge AI bet, and 5 ASX small caps to watch
Expert says buy US bonds now to lock in yields Viking Therapeutics doubled and Janux Therapeutics tripled after updates Microsoft makes another huge AI [more…]
BPM Minerals is spinning the drill bit at Claw looking for more gold in high-grade territory
BPM’s 10,000m drilling campaign at Claw is 60% complete Claw is along strike of Capricorn Metals’ 3.24Moz Mt Gibson mine Assays due in late March [more…]
Belararox launches into fieldwork at Tambo South, a target with similar characteristics to the nearby BHP-backed Filo Del Sol
Field work at the Tambo South target has started comprising surface sampling and geological mapping The start of these activities means exploration over the TMT [more…]
What KPMG reckons about fintechs in 2024 and ASX players to watch – Part One
KPMG says many fintechs have had to rethink their growth plans amidst falling investor sentiment and higher costs Indian-focused fintech Findi has defied the odds [more…]
Bulk Buys: As iron ore hits first bump of 2024 road, Vale pledges focus on quality
Vale reported a strong fourth quarter, but has pledged to add quality tonnes in iron ore rather than just boost scale Executives at the Brazilian [more…]
Why Smackover’s history of oil production could translate to cheap lithium brine for Pantera Minerals
Lithium might be experiencing a downturn at the moment but there’s little doubt that demand for the battery metal will return stronger than ever as [more…]
Brainchip’s potential in Edge AI is undeniable, but can sales catch up with its cash burn?
Brainchip is operating in the biggest megatrend today, AI microchips BRN’s shares have surged 200pc this year, but the company faces obstacles Can BRN’s sales [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 28 February, 2024 – an important day in the world of Being an Excellent Christian, because it was [more…]
What’s in store for 2024: Paradigm Biopharmaceuticals
Stockhead’s Ashtyn Hiron sits down with Paradigm Biopharmaceuticals (ASX:PAR) managing director Paul Rennie to close the books on 2023 and gain a sneak peek into [more…]
